Posted on Jan 4, 2016 7:43:01 AM by Rebecca Anderson

OAB Study: Patients Prefer PTNS to Other 3rd-Line Treatments

Patient pondering his options

Finding the right treatment for some OAB patients is like looking for a needle in a painful, ineffective, invasive, side-effect filled haystack. Now, though, we have comforting news about patient response to an effective 3rd-line treatment. A new study out of the United Kingdom (UK) finds that when presented with a choice, refractory OAB patients preferred percutaneous tibial nerve stimulation (PTNS) to other 3rd-line treatments. The results should interest both medical professionals and patients given that PTNS therapy delivered via Urgent PC has already proven to be a highly effective, virtually painless and side-effect free treatment option. 

Three 3rd-Line Treatments Were Evaluated

Various studies suggest that globally, 50-100 million people may suffer from overactive bladder. The UK study included only male and female OAB refractory patients who had used medication therapy. Researchers asked patients to consider three dramatically different 3rd-line treatments:

  • Sacral Neuromodulation (SNM) – Surgically implanting a programmable stimulator to deliver low amplitude electrical stimulation to the sacral nerve.
  • Onabotulinumtoxin A - Injections of Botox® into the bladder muscle.
  • Percutaneous tibial nerve stimulation (PTNS) - An effective, outpatient method of providing neuromodulation via the tibial nerve to the sacral plexus.

Researchers found 81% of the patients who had experience with OAB medications were willing to try all three 3rd-line treatments. However, after rating them, 98% of the participants expressed a willingness to try PTNS therapy and 57% preferred PTNS therapy most among the three therapies. In fact, even those participants who viewed onabotulinumtoxin A as most effective wanted to start with PTNS therapy.In addition, researchers discovered that patients were greatly influenced by characteristics of each treatment. Using best-worst scaling (BWS), OAB patients “prioritized subsets of 13 treatment characteristics (attributes) across 13 choice tasks.” For example, the implant required by SNM, and the delivery of the botulinum toxin via the urethra were seen as negatives by respondents. Regularly scheduled visits decreased the BWS ratings for PTNS, while “needle inserted in ankle,” and “minimal side effects” were viewed as positives.

Discussing 3rd-line Treatments Makes a Difference

For medical professionals, one of the positive takeaways from this study is the conclusion that if you discuss everything that’s involved with the various treatments, it does help patients make their decisions, and it makes them more satisfied with the OAB treatment they choose. This is important, because finding a treatment that is effective and satisfying to patients can be a major challenge.

Consider this, medication therapy causes problems for many patients because of the side-effects. A majority of these patients stop using their meds within 90-days, and 80% stop altogether within one year. In addition, research shows troubling links between some OAB medications and dementia in the elderly. This study suggests that patients who can’t tolerate the OAB drugs may be willing to try PTNS via the Urgent PC Neuromodulation System, which has virtually no side-effects and has proven clinically effective in 60-80% of patients.

Urgent PC requires 12-weeks of 30-minute outpatient sessions for a mild electrical stimulation of bladder muscles and nerves. Improvement begins within 6-8 weeks, though the full 12-sessions are recommended, along with limited follow-up treatment.

Losing Patients to OAB

 

Urgent PC is indicated for the treatment of Overactive Bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence. Treatment with Urgent PC is contraindicated for patients with pacemakers or implantable defibrillators, patients prone to excessive bleeding, patients with nerve damage that could impact either percutaneous tibial nerve or pelvic floor function or patients who are pregnant or planning to become pregnant during the duration of the treatment. Most patients don't experience side-effects. If side-effects occur, they are typically temporary and include mild pain and skin inflammation at or near the stimulation site. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician. For complete instructions for use, storage, warnings, indications, contraindications, precautions, adverse reactions and disclaimer of warranties, please refer to the insert accompanying each product or online at www.cogentixmedical.com. Urgent PC is a registered trademark of Cogentix Medical © 2015 Cogentix Medical. All rights reserved. 

Rebecca Anderson
Rebecca Anderson has been a marketer in the healthcare industry for over fifteen years, the last ten of which have been focused on Urgent PC and other products from Cogentix Medical. Rebecca has a special fondness for Urgent PC, having been part of the Uroplasty team that launched the product to U.S. and International markets.
Return To Blog